Bone Marrow Transplantation News

The adoption of healthy lifestyle practices may prevent a large proportion of cancers and reduce cancer mortality in the United States, according to results of a prospective cohort study.

The use of chlorhexidine gluconate wipes for patient hygiene may lower central line-associated bloodstream infection rates among patients with cancer, according to the results of a study presented at the Oncology Nursing Society Annual Congress.

Patients treated in phase 1 trials designed with a biomarker-based approach for treatment selection demonstrated higher response rates and longer PFS, according to results of a meta-analysis scheduled for presentation at the ASCO Annual Meeting.

The U.S. House Energy Subcommittee on Health today held a hearing to offer doctor and patient perspectives on planned changes to the Medicare Part B drug reimbursement model.

The FDA today granted accelerated approval to nivolumab for treatment of certain patients with classical Hodgkin lymphoma.

Preliminary data from a small randomized study showed light therapy decreased depressive symptoms and normalized circadian rhythms among cancer survivors.

Heather S.L. Jim, PhD, of the health outcomes and behavior program at Moffitt Cancer Center, and colleagues analyzed data from previously published studies that examined spirituality and its association with outcomes among more than 32,000 patients with cancer. They found that patients with higher levels of spiritual well-being reported better emotional, physical and social health.

The administration of cyclophosphamide following a mobilized blood cell transplant appeared associated with a lower incidence of chronic graft-versus-host disease, according to findings from a study conducted at Fred Hutchinson Cancer Research Center.

Examination of pretreatment gut microbiome could identify patients at high risk for bloodstream infection after allogeneic hematopoietic stem cell transplantation, according to a recently published study.

The cost of oral cancer drugs in their first year on the market has increased significantly since the year 2000, according to a research letter published in JAMA Oncology.